One-Year Outcomes Using Ranibizumab for Neovascular Age-Related Macular Degeneration: Results of a Prospective and Retrospective Observational Multicentre Study

Table 3

VFQ-25 subscale and total scores at 3 and 12 months. Values are shown as mean ± SD.

Subscale	Month 3				Month 12
	𝑛	Baseline	Month 3	𝑃-value^†	𝑛	Baseline	Month 12	𝑃-value^†
General health	130	52.5±21.8	51.9±20.6	0.718	89	53.9±23.5	52.0±23.0	0.404
General vision	129	51.0±19.8	59.2±18.3	<0.001	89	52.1±19.7	60.2±18.7	<0.001
Ocular pain	131	80.0±21.8	85.0±17.6	0.001	91	81.7±21.1	85.7±17.0	0.081
Near activities	131	58.9±18.7	63.2±19.0	<0.001	91	60.2±18.6	64.3±19.7	0.029
Distance activities	131	64.4±20.3	66.7±20.1	0.026	91	66.8±18.8	68.1±20.1	0.435
Vision specific:
Social functioning	130	79.5±21.8	80.9±19.8	0.213	90	82.1±19.7	82.0±18.5	0.760
Mental health	131	59.6±28.7	65.7±27.9	<0.001	91	61.9±27.3	66.0±28.3	0.055
Role difficulties	129	61.7±29.5	62.7±29.3	0.720	89	64.9±28.7	63.8±28.6	0.636
Dependency	128	74.8±31.7	75.6±31.6	0.439	89	79.6±30.5	75.8±31.7	0.152
Driving	65	60.7±33.8	61.1±35.6	0.897	47	63.3±30.2	57.6±31.8	0.044
Colour vision	124	82.9±19.9	83.7±20.1	0.568	86	83.5±18.7	81.9±19.1	0.328
Peripheral vision	125	70.6±20.6	72.3±21.1	0.153	85	72.2±19.0	72.2±21.2	0.884
VFQ-25 total	131	67.4 ± 19.3	70.6 ± 19.0	<0.001	91	69.9 ± 17.8	70.9 ± 18.4	0.389

^†Wilcoxon signed rank test.